$BIOD handle at resistance $0.439 Nasdaq CM We
Post# of 98044
Posted On: 09/10/2016 6:30:56 PM
$BIOD handle at resistance $0.439
Nasdaq CM
Website
Low Float
Shares Outstanding 64.15M
Float 60.35M
% Held by Insiders 5.66%
% Held by Institutions 84.30%
Shares Short 98.79k
Short Ratio 0.17
Short % of Float 0.15%
Shares Short (prior month) 44.21k
Headlines
and Filings
Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company completed a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-531, a concentrated ultra-rapid-acting insulin formulation. In addition, the company develops pre-clinical analog-based ultra-rapid-acting insulin formulations using insulin lispro, the active pharmaceutical ingredient in Humalog, as well as insulin aspart, the active pharmaceutical ingredient in NovoLog. Biodel Inc. was founded in 2003 and is headquartered in Danbury, Connecticut.
Nasdaq CM
Website
Low Float
Shares Outstanding 64.15M
Float 60.35M
% Held by Insiders 5.66%
% Held by Institutions 84.30%
Shares Short 98.79k
Short Ratio 0.17
Short % of Float 0.15%
Shares Short (prior month) 44.21k
Headlines
and Filings
Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company completed a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-531, a concentrated ultra-rapid-acting insulin formulation. In addition, the company develops pre-clinical analog-based ultra-rapid-acting insulin formulations using insulin lispro, the active pharmaceutical ingredient in Humalog, as well as insulin aspart, the active pharmaceutical ingredient in NovoLog. Biodel Inc. was founded in 2003 and is headquartered in Danbury, Connecticut.
(0)
(0)Scroll down for more posts ▼